Sio Gene Therapies Inc SIOX:NASDAQ

RT Quote | NASDAQ | USD
Last | 04/16/21 EDT
2.45quote price arrow down-0.02 (-0.81%)
Volume
362,291
52 week range
1.86 - 5.74

...

Loading . . .
  • Open2.47
  • Day High2.47
  • Day Low2.38
  • Prev Close2.47
  • 52 Week High5.74
  • 52 Week High Date10/05/20
  • 52 Week Low1.86
  • 52 Week Low Date11/02/20

Key Stats

  • Market Cap143.94M
  • Shares Out58.75M
  • 10 Day Average Volume0.53M
  • Dividend-
  • Dividend Yield-
  • Beta1.70
  • YTD % Change-11.87

KEY STATS

  • Open2.47
  • Day High2.47
  • Day Low2.38
  • Prev Close2.47
  • 52 Week High5.74
  • 52 Week High Date10/05/20
  • 52 Week Low1.86
  • 52 Week Low Date11/02/20
  • Market Cap143.94M
  • Shares Out58.75M
  • 10 Day Average Volume0.53M
  • Dividend-
  • Dividend Yield-
  • Beta1.70
  • YTD % Change-11.87

RATIOS/PROFITABILITY

  • EPS (TTM)-1.15
  • P/E (TTM)-2.13
  • Fwd P/E (NTM)-3.10
  • EBITDA (MRQ)-45.067M
  • ROE (MRQ)-97.24%
  • Revenue (MRQ)0.00
  • Gross Margin (MRQ)-
  • Net Margin (MRQ)-
  • Debt To Equity (MRQ)0.00%

EVENTS

  • Earnings Date06/11/2021
  • Ex Div Date-
  • Div Amount-
  • Split Date-
  • Split Factor-

Latest From Sio Gene Therapies Inc

There is no recent news for this security.

Latest From Our Partners

Profile

MORE
Sio Gene Therapies Inc., together with its wholly owned subsidiaries, is a clinical-stage company focused on developing gene therapies for neurodegenerative diseases. The Company is developing a pipeline of product candidates for the treatment of these debilitating diseases, including Parkinson's disease, GM1 gangliosidosis and GM2 gangliosidosis (including Tay-Sachs disease and Sandhoff disease). The Company’s subsidiaries include Axovant Holdings Ltd, Axovant Sciences Inc...
Address
130 West 42Nd Street, 26Th Floor
New York, NY
10036
United States

Top Peers

SYMBOLLASTCHG%CHG
LYRA
Lyra Therapeutics Inc
10.47-0.36-3.32%
ATNM
Actinium Pharmaceuticals Inc
7.46-0.11-1.45%
EVFM
Evofem Biosciences Inc
1.56UNCHUNCH
GALT
Galectin Therapeutics Inc
2.19-0.04-1.79%
NBSE
NeuBase Therapeutics Inc
6.06-0.44-6.77%